Design and characterization of optimized adenosine A 2A/A 1 receptor antagonists for the treatment of Parkinson's disease

Journal of Medicinal Chemistry

Volumn 55, Issue 3, 2012, Pages 1402-1417

  Shook, Brian C ^a   Rassnick, Stefanie ^a   Wallace, Nathaniel ^a   Crooke, Jeffrey ^a   Ault, Mark ^a   Chakravarty, Devraj ^a   Barbay, J Kent ^a   Wang, Aihua ^a   Powell, Mark T ^a   Leonard, Kristi ^a   Alford, Vernon ^a   Scannevin, Robert H ^a   Carroll, Karen ^a   Lampron, Lisa ^a   Westover, Lori ^a   Lim, Heng Keang ^a   Russell, Ronald ^a   Branum, Shawn ^a   Wells, Kenneth M ^a   Damon, Sandra ^a   Youells, Scott ^a   Li, Xun ^a   Beauchamp, Derek A ^a   Rhodes, Kenneth ^a   Jackson, Paul F ^a   more..

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(BIS TERT BUTOXYCARBONYL)AMINO] 5 OXO 4 PHENYL 5H INDENO[1,2 D]PYRIMIDINE 8 CARBOXYLIC ACID; 2 AMINO 4 PHENYL 8 (PYRIDIN 3 YLMETHYL) 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 AMINO 8 (2 MORPHOLINOETHOXY) 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 AMINO 8 (4 METHYLPIPERAZINE 1 CARBONYL) 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 AMINO 8 [(2,5 DIMETHYLPYRROLIDIN 1 YL)METHYL] 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 AMINO 8 [(3 FLUOROPYRIDIN 4 YL)METHYL] 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 AMINO 8 [(4 CHLOROPYRIDIN 3 YL)METHYL] 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 AMINO 8 [(5 FLUOROPYRIDIN 3 YL)METHYL] 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 AMINO 8 [DIFLUORO(PYRIDIN 3 YL)METHYL] 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 AMINO 8 HYDROXY 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 AMINO 8 METHOXY 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 AMINO 8 NICOTINOYL 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; 2 BENZYLIDENE 6 METHOXY 2,3 DIHYDRO 1H INDEN 1 ONE; 5 [(2 AMINO 5 OXO 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 8 YL)METHYL]NICOTINONITRILE; 8 (7 AZABICYCLO[2.2.1]HEPTAN 7 YLMETHYL) 2 AMINO 4 PHENYL 5H INDENO[1,2 D]PYRIMIDIN 5 ONE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG DESIGN; DRUG METABOLISM; DRUG STRUCTURE; FEMALE; GENOTOXICITY; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; RAT;

ADENOSINE A1 RECEPTOR ANTAGONISTS; ADENOSINE A2 RECEPTOR ANTAGONISTS; ADMINISTRATION, ORAL; ANIMALS; DRUG DESIGN; FEMALE; INDENES; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; PARKINSONIAN DISORDERS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863128712     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201640m     Document Type: Article

References (69)

1. Lozano, A. M.; Lang, A. E.; Hutchison, W. D.; Dostrovsky, J. O. New developments in understanding the etiology of Parkinson's disease and in its treatment Curr. Opin. Neurobiol. 1998, 8, 783-790 (Pubitemid 28564477)
2. 2 dopamine receptors in rat striatum Mol. Brain Res. 1992, 14, 186-195
3. 2receptor mRNA in the human brain Neurosci. Lett. 1991, 130, 177-181
4. Olanow, C. W. MAO-B inhibitors in Parkinson's disease Adv. Neurol. 1993, 60, 666-671
5. Gordin, A.; Brooks, D. J. Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease J. Neurol. 2007, 254, IV/37-IV/48
6. Olanow, C. W.; Stocchi, F. COMT inhibitors in Parkinson's disease. Can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004, 62, S72-S81
7. 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson's disease Neurology 2011, 76, 1811-1816
8. Antonini, A.; Clilia, R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: Incidence, neurobiological basis, management and prevention Drug Saf. 2009, 32, 475-488
9. Hansard, M. J.; Smith, L. A.; Jackson, M. J.; Cheetham, S. C.; Jenner, P. Dopamine, but not norepinephrine or serotonin reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates J. Pharmacol. Exp. Ther. 2002, 303, 952-958 (Pubitemid 35424376)
10. Antonini, A.; Tolosa, E.; Mizuno, Y.; Yamamoto, M.; Poewe, W. H. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease Lancet Neurol. 2009, 8, 929-937
11. Yamamoto, M.; Schapira, A. H. V. Dopamine agonists in Parkinson's disease Expert Rev. Neurother. 2008, 8, 671-677 (Pubitemid 351551017)
12. 2A receptor antagonists and Parkinson's disease ACS Chem. Neurosci. 2011, 2, 555-567
13. 2A antagonists 1,2,4-triazolo[1,5-c]pyrimidines Bioorg. Med. Chem. Lett. 2009, 19, 967-971
14. 2A receptor antagonists with in vivo activity J. Med. Chem. 2008, 51, 400-406 (Pubitemid 351252268)
15. 2A receptor antagonists Bioorg. Med. Chem. Lett. 2009, 19, 1399-1402
16. 2A receptor antagonists J. Med. Chem. 2004, 47, 4291-4299 (Pubitemid 39045435)
17. Latini, S.; Pedata, F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations J. Neurochem. 2001, 79, 463-484 (Pubitemid 33029920)
18. Dunwiddie, T. V.; Masino, S. A. The role and regulation of adenosine in the central nervous system Annu. Rev. Neurosci. 2001, 24, 31-55 (Pubitemid 32695222)
19. Stiles, G. L. Adenosine receptors J. Biol. Chem. 1992, 267, 6451-6454
20. 2A receptors in rat central nervous system J. Comp. Neurol. 1998, 401, 163-186 (Pubitemid 28481960)
21. 2A receptors-where are they? What do they do? Comments Trends Pharmacol. Sci. 1998, 19, 46-47
22. 11C]TMSX Synapse 2005, 55, 133-136 (Pubitemid 39665672)
23. Svenningsson, P.; Hall, H.; Sedvall, G.; Fredholm, B. B. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study Synapse 1997, 27, 322-335 (Pubitemid 27479470)
24. 2A adenosine receptor overexpression and functionality, as well as TNF-α levels, correlate with motor symptoms in Parkinson's disease FASEB J. 2010, 24, 587-598
25. Pollack, A. E.; Fink, J. S. Adenosine antagonists potentiate D2 dopamine dependent activation of Fos in the striatopallidal pathway Neuroscience 1995, 68, 721-728
26. Duty, S.; Jenner, P. Animal models of Parkinson's disease: A source of novel treatments and clues to the cause of the disease Br. J. Pharmacol. 2011, 164, 1357-1391
27. 2A adenosine receptor inactivation in a model of Parkinson's disease J. Neurosci. 2001, 21, RC143/1-RC143/6
28. 2A receptor antagonist in MPTP-treated monkeys Neurology 1999, 52, 1673-1677 (Pubitemid 29220647)
29. 2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes Drug Dev. Res. 2001, 52, 379-386 (Pubitemid 32401962)
30. 2A receptor blockade in experimental models of Parkinson's disease J. Neurochem. 2002, 80, 262-270 (Pubitemid 34809371)
31. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann. Neurol. 1998, 43, 507-513 (Pubitemid 28231727)
32. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats Eur. J. Pharmacol. 2000, 408, 249-255
33. Neustadt, B. R.; Hao, J.; Lindo, N.; Greenlee, W. J.; Stamford, A. W.; Tulshian, D.; Ongini, E.; Hunter, J.; Monopoli, A.; Bertorelli, R.; Foster, C.; Arik, L.; Lachowicz, J.; Ng, K.; Feng, K. I. Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines Bioorg. Med. Chem. Lett. 2007, 17, 1376-1380 (Pubitemid 46240836)
34. Hodgson, R. A.; Bertorelli, R.; Varty, G. B.; Lachowicz, J. E.; Forlani, A.; Fredduzzi, S.; Cohen-Williams, M. E.; Higgins, G. A.; Impagnatiello, F.; Nicolussi, E.; Parra, L. E.; Foster, C.; Zhai, Y.; Neustadt, B. R.; Stamford, A. W.; Parker, E. M.; Reggiani, A.; Hunter, J. C. Characterization of the potent and highly selective 2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4, 3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression J. Pharmacol. Exp. Ther. 2009, 330, 294-303
35. 2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys Exp. Neurol. 2000, 162, 321-327 (Pubitemid 30217727)
36. 2A receptor antagonist istradefylline in advanced PD Neurology 2003, 61, 297-303 (Pubitemid 36975955)
37. 2A receptor antagonist treatment of Parkinson's disease Neurology 2003, 61, 293-296 (Pubitemid 36975954)
38. 11C]8- dicyclopropylmethyl-1-methyl-3-propylxanthine Nuclear Med. Biol. 2004, 31, 975-981 (Pubitemid 39647664)
39. 1 receptor agonist, on spontaneous and evoked dopamine release in rat neostriatum Neurosci. Lett. 1995, 185, 29-32
40. Moore, K. A.; Nicoll, R. A.; Schmitz, D. Adenosine gates synaptic plasticity at hippocampal mossy fiber synapses Proc. Nat. Acad. Sci. 2003, 100, 14397-14402 (Pubitemid 37499248)
41. 1 receptors in nerve terminal and synapses of the rat hippocampus Brain Res. 2003, 987, 49-58 (Pubitemid 37267886)
42. 1 receptors J. Pharmacol. Sci. 2004, 96, 42-52 (Pubitemid 39318777)
43. 2A receptor antagonists and their pharmaceutical compositions. PCT Int. Appl. WO 2005040151, 2005.
44. 2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs Behav. Brain Res. 2008, 194, 152-161
45. 2A receptor antagonist, ASP5854, in rhesus monkeys: Relationship to anticataleptic effect J. Nucl. Med. 2008, 49, 1183-1188 (Pubitemid 351948029)
46. 2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1- isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition J. Pharmacol. Exp. Ther. 2007, 323, 708-719 (Pubitemid 350005141)
47. 1 Receptor Antagonist in Animal Models of Parkinson's Disease J. Med. Chem. 2010, 53, 8104-8115
48. 1 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 2864-2867
49. 1 antagonists Bioorg. Med. Chem. Lett. 2010, 20, 2868-2871
50. Zarrindast, M. R.; Modabber, M.; Sabetkasai, M. Influence on different adenosine receptor subtypes on catalepsy in mice Psychopharmacology 1993, 113, 257-261 (Pubitemid 24002002)
51. 2 receptors modulate haloperidol-induced catalepsy in rats Eur. J. Pharmacol. 1997, 328 (2/3) 135-141 (Pubitemid 27263351)
52. Cooper, D. R.; Marrel, C.; van de Waterbeemd, H.; Testa, B.; Jenner, P.; Marsden, C. D. L-Dopa esters as potential prodrugs: Behavioral activity in experimental models of Parkinson's disease J. Pharm. Pharmacol. 1987, 39, 627-635 (Pubitemid 17116308)
53. Ungerstedt, U. 6-Hydroxydopamine-induced generation of central monoamine neurons Eur. J. Pharmacol. 1968, 5, 107-110
54. Ungerstedt, U.; Arbuthnott, G. W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 1970, 24, 485-493
55. Luthman, J.; Fredriksson, A.; Sundstroem, E.; Jonsson, G.; Archer, T. Selective lesion of central dopamine or moradenaline neuron systems in the neonatal rat: Motor behavior and monoamine alteration at adult stage Behav. Brain Res. 1989, 33, 267-277 (Pubitemid 19160683)
56. Bankiewicz, K. S. MPTP-induced parkinsonism in nonhuman primates Methods Neurosci. 1991, 7, 168-182
57. Jakowec, M. W.; Petzinger, G. M. 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced lesion model of Parkinson's disease, with emphasis on mice and nonhuman primates Comp. Med. 2004, 54, 497-513 (Pubitemid 39557443)
58. Campos-Romo, A.; Ojeda-Flores, R.; Moreno-Briseno, P.; Fernandez-Ruiz, J. Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the hallway task J. Neurosci. Methods 2009, 177, 361-368
59. 1 antagonist by minimizing bioactivation to an iminium ion reactive intermediate Chem. Res. Toxicol. 2011, 24, 1012-1030
60. Hyttel, J.; Larsen, J. J.; Christensen, A. V.; Arnt, J. Receptor-binding profiles of neuroleptics Psychopharmacol. Suppl. 1985, 2, 9-18
61. Kraus, G. A.; Sy, J. O. A synthetic approach to rocaglamide via reductive cyclization of δ-keto nitriles J. Org. Chem. 1989, 54, 77-83
62. 2A receptor antagonists. PCT Int. Appl. WO 2005042500, 2005.
63. Yu, Y.; Liebeskind, L. S. Copper-mediated, palladium-catalyzed coupling of thiol ester with aliphatic organoboron reagents J. Org. Chem. 2004, 69, 3554-3557 (Pubitemid 38621307)
64. Kusturin, C.; Liebeskind, L. S.; Rahman, H.; Sample, K.; Schweitzer, B.; Srogl, J.; Neumann, W. L. Switchable catalysis: Modular synthesis of functionalized pyrimidones via selective sulfide and halide cross-coupling chemistry Org. Lett. 2003, 5, 4349-4352 (Pubitemid 37490626)
65. Liebeskind, L. S.; Srogl, J. Heteroaromatic thioether-boronic acid cross-coupling under neutral reaction conditions Org. Lett. 2002, 4, 979-981
66. Marsden, C. D.; Dolphin, A.; Duvoisin, R. C.; Jenner, P.; Tarsy, D. Role of noradrenaline in levodopa reversal of reserpine akinesia Brain Res. 1974, 17, 521-525
67. 2 dopamine agonists in reserpine-treated mice Psychopharmacology 1994, 114, 495-504
68. Robinson, T. E.; Becker, J. B. The rotational behavior model: Asymmetry in the effects of unilateral 6-OHDA lesions of the substantia nigra in rats Brain Res. 1983, 264, 127-131 (Pubitemid 13111237)
69. Damier, P.; Hirsch, E. C.; Agid, Y.; Graybiel, A. M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease Brain 1999, 122, 1437-1448 (Pubitemid 29374122)